Pompano Beach, FL, Nov. 07, 2017 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC PINK: BSEM) (the “Company”) announced today that, Qualified Pharma Ingredients, Inc. (QPI), an Active Pharmaceutical Ingredients supplier, has begun expansion of its facility to 4,500 square feet. The construction is expected to take 6 weeks and will provide additional product storage, pack out stations, and a Schedule III-V DEA cage, allowing QPI to expand its product portfolio to include DEA regulated products.
DrDavesBest.com has launched a newly developed, marketing optimized website for the Company’s e-commerce division. The Company recently launched a marketing initiative to grow the sales of its nutraceutical products, including the hiring of an in-house marketing executive. Company CEO, Henry Van Vurst stated, “One of our first strategic moves in expanding our customer base is to attract a younger market, and we are eager to see how the new look and navigation tools perform.”
About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies, Inc., is a global life sciences corporation, focused on providing world-class technologies with a concentration in Pharmaceuticals, Wellness, Regenerative Medicine and Blue Technologies. We continuously innovate through the inclusion of complementary companies and a diversified technology portfolio. This improves the Quality of Life for our consumers and, as a result, maximizes shareholder value.
Forward-Looking Statements: Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” believe” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.